Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2016

GlobalData
77 Pages - GLDATA57813
$2,500.00

Summary

GlobalData's clinical trial report, “Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2016" provides an overview of Exocrine Pancreatic Insufficiency clinical trials scenario. This report provides top line data relating to the clinical trials on Exocrine Pancreatic Insufficiency. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Abbott Laboratories
Anthera Pharmaceuticals Inc
Aptalis Pharmatech Inc
AbbVie Inc
Allergan Plc
Digestive Care Inc
DATAMAP GmbH
Parexel International Corp
Axcan Pharma Inc
Cystic Fibrosis Foundation

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Exocrine Pancreatic Insufficiency 32
Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients 32
Clinical Trial Profile Snapshots 33
Appendix 74
Abbreviations 74
Definitions 74
Research Methodology 75
Secondary Research 75
About GlobalData 76
Contact Us 76
Disclaimer 76
Source 77

List of Tables
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Region, 2016* 6
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 10
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 16
Exocrine Pancreatic Insufficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Exocrine Pancreatic Insufficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 19
Exocrine Pancreatic Insufficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20
Exocrine Pancreatic Insufficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Phase, 2016* 22
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26
Exocrine Pancreatic Insufficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31

List of Figures
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 10
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
Exocrine Pancreatic Insufficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Exocrine Pancreatic Insufficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 19
Exocrine Pancreatic Insufficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20
Exocrine Pancreatic Insufficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23
Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26
Exocrine Pancreatic Insufficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31
GlobalData Methodology 75

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports